Last reviewed 2026-04-19 · How we verify

Sulforaphane Nutraceutical

Sheppard Pratt Health System · Phase 2 active Small molecule

Sulforaphane Nutraceutical is a Small molecule drug developed by Sheppard Pratt Health System. It is currently in Phase 2 development. Also known as: Avmacol®.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Sulforaphane Nutraceutical
Also known as	Avmacol®
Sponsor	Sheppard Pratt Health System
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Sulforaphane Nutraceutical CI brief — competitive landscape report
Sulforaphane Nutraceutical updates RSS · CI watch RSS
Sheppard Pratt Health System portfolio CI

Frequently asked questions about Sulforaphane Nutraceutical

What is Sulforaphane Nutraceutical?

Sulforaphane Nutraceutical is a Small molecule drug developed by Sheppard Pratt Health System.

Who makes Sulforaphane Nutraceutical?

Sulforaphane Nutraceutical is developed by Sheppard Pratt Health System (see full Sheppard Pratt Health System pipeline at /company/sheppard-pratt-health-system).

Is Sulforaphane Nutraceutical also known as anything else?

Sulforaphane Nutraceutical is also known as Avmacol®.

What development phase is Sulforaphane Nutraceutical in?

Sulforaphane Nutraceutical is in Phase 2.

Manufacturer: Sheppard Pratt Health System — full pipeline
Also known as: Avmacol®

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing